Tumor microenvironment responsive FePt/MoS₂ nanocomposites with chemotherapy and photothermal therapy for enhancing cancer immunotherapy

Abstract

As a multifunctional platform for photo-chemo-immunotherapy strategies, FePt/MoS2 nanocomposites shows great potential in cancer theranostic.

NIR Laser Responsive Nanoparticles for Ovarian Cancer Targeted Combination Therapy with Dual-modal Imaging Guidance

“…The EE and DL of the FBPD NPs were calculated by UV spectrophotometry. UV-spectra of Dox dispersed in saline at different concentrations (20,25,30,35,40, and 50 µg/mL) and the corresponding relationship between concentrations of Dox and absorbance ( Fig. 2e, 2f).…”

“…One probable approach to optimize their therapeutic effects is to combine PTT with other types of treatments. It was reported that PTT and chemo-drug synergistically enhance the antitumor effect to a great extent [21][22][23][24][25]. Due to the post-X-ray bombardment, the secondary electrons were distributed to enhance the EPR effect, and consequently, high-Z nanomaterials could optimize the passive tumor targeting.…”

Tumor Microenvironment Sensitive Nanocarriers for Bioimaging and Therapeutics

“…anchored the following three components, i) FePt nanoparticles, which also has Fenton catalyst‐like property, ii) folic acid, and iii) CpG oligonucleotide onto the surface of molybdenum sulfate (MoS 2 ) nanosheets, to construct nanocomposites for combination therapy. [ 64 ] As anticipated, the ferroptosis agent, FePt, produced cytotoxic ROS through Fenton reaction, and the MoS 2 presented effective photothermal effect under NIR laser irradiation. Further, the CpG oligonucleotide induced antitumor immunity with the help of anti‐cytotoxic T‐lymphocyte‐associated protein 4 checkpoint‐blockade.…”

The epigenetic regulators and metabolic changes in ferroptosis-associated cancer progression

“…Interestingly, FePt nanoparticles, a novel ferroptosis agent, could induce ferroptosis by catalyzing the Fenton reaction to produce the ROS. Meanwhile, the metastatic tumors are abolished effectively with the support of oligodeoxynucleotides containing cytosine-guanine together with systemic checkpoint blockade immunotherapy using an anti-CTLA4 (anti-cytotoxic T lymphocyte associated antigen-4) antibody [145], providing a multifunctional platform for anticancer therapeutic applications through ferroptosis. Targeting ferroptosis holds novel promise for the treatment of cancer and considerable efforts are being made to generate ferroptosis modulators for clinical use, but additional studies are required to devise the most efficient strategies in epigenetic and metabolic regulation of ferroptosis.…”